While PD-1 blocking antibodies appear to be associated with positive effects on their own, it is reasonable to question whether the combination of this treatment with compounds that are already used in MPN could provide greater benefits to patients. The gene discussed is PDCD1; the disease is myeloproliferative neoplasm.